Researchers are reshaping the fight against acute leukemia with a wave of innovative drugs and cell‑based treatments that are easier for patients to tolerate and more likely to keep the disease in check. First, a drug called Inotuzumab ozogamicin (INO) works like a guided missile, delivering chemotherapy straight to cancer‑ous B cells that carry the CD22 marker. It has produced high remission rates and can help patients reach a transplant without the heavy side‑effects of traditional chemo. The biggest buzz, however, surrounds CAR‑T cell therapy – a personalized immunotherapy where a patient’s own immune cells are re‑engineered to hunt leukemia. CD19‑targeted CAR‑T is now the go‑to second‑line option for relapsed B‑cell ALL, delivering over 90 % complete remission in children and young adults and showing durable responses for years. New versions that also target CD22, or combine CD19 and CD22, are being tested to prevent the cancer from slipping away by losing one marker. For AML, about one‑fifth of patients carry IDH1/2 mutations. Adding the IDH inhibitors ivosidenib or enasidenib to standard chemotherapy or to azacitidine‑venetoclax has pushed three‑year survival up to 60‑80 %. The AZA/IVO combo is now the recommended low‑intensity regimen for IDH‑mutated AML. A fresh class of “menin” inhibitors (revumenib, zifitomenib) is showing striking response rates—up to 100 % when paired with standard chemo—in AML subtypes driven by KMT2A rearrangements or NPM1 mutations. T‑cell ALL presents a tougher puzzle because its targets are also on healthy T cells, leading to “fratricide” and severe immune depletion. Early trials of CD7‑ and CD5‑directed CAR‑T have achieved rapid remissions, but long‑term survival remains limited. To overcome these hurdles, scientists are engineering universal CAR‑T cells and CAR‑NK cells using CRISPR‑based gene editing, which can sidestep fratricide and graft‑versus‑host disease. Early pediatric cases of T‑ALL treated with edited CAR‑T cells have stayed in remission without serious complications. Together, these advances promise a future where acute leukemia can be tackled with precision, fewer side effects, and lasting cures.
Read more